Home Federal Bank of Tennessee Acquires 85 Shares of Amgen Inc. (NASDAQ:AMGN)

Home Federal Bank of Tennessee lifted its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 4.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,135 shares of the medical research company’s stock after purchasing an additional 85 shares during the period. Home Federal Bank of Tennessee’s holdings in Amgen were worth $519,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Ignite Planners LLC grew its holdings in shares of Amgen by 17.9% during the second quarter. Ignite Planners LLC now owns 1,119 shares of the medical research company’s stock worth $276,000 after purchasing an additional 170 shares during the last quarter. HB Wealth Management LLC grew its holdings in shares of Amgen by 14.8% during the second quarter. HB Wealth Management LLC now owns 25,036 shares of the medical research company’s stock worth $6,091,000 after purchasing an additional 3,234 shares during the last quarter. Ritholtz Wealth Management grew its holdings in shares of Amgen by 11.6% during the second quarter. Ritholtz Wealth Management now owns 12,866 shares of the medical research company’s stock worth $3,130,000 after purchasing an additional 1,334 shares during the last quarter. Five Oceans Advisors lifted its stake in shares of Amgen by 5.3% in the second quarter. Five Oceans Advisors now owns 1,093 shares of the medical research company’s stock worth $266,000 after acquiring an additional 55 shares during the period. Finally, Miracle Mile Advisors LLC lifted its stake in shares of Amgen by 181.0% in the second quarter. Miracle Mile Advisors LLC now owns 3,130 shares of the medical research company’s stock worth $761,000 after acquiring an additional 2,016 shares during the period. 77.14% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In related news, Director R Sanders Williams sold 200 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $249.96, for a total transaction of $49,992.00. Following the sale, the director now owns 5,301 shares of the company’s stock, valued at approximately $1,325,037.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Robert Eckert sold 6,600 shares of the stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the sale, the director now owns 21,184 shares of the company’s stock, valued at approximately $5,274,816. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Sanders Williams sold 200 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $249.96, for a total value of $49,992.00. Following the sale, the director now directly owns 5,301 shares in the company, valued at approximately $1,325,037.96. The disclosure for this sale can be found here. 0.46% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. TheStreet raised Amgen from a “c+” rating to a “b” rating in a research note on Monday, August 15th. Robert W. Baird reissued an “underperform” rating and issued a $185.00 price target on shares of Amgen in a research note on Tuesday, September 13th. Piper Sandler boosted their price target on Amgen from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, August 5th. Atlantic Securities dropped their price target on Amgen from $190.00 to $182.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 9th. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $241.13.

Amgen Stock Performance

NASDAQ:AMGN traded down $1.67 during trading on Friday, reaching $226.08. The company’s stock had a trading volume of 63,913 shares, compared to its average volume of 2,761,167. The firm has a market cap of $120.94 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 1.81 and a beta of 0.56. The company has a debt-to-equity ratio of 14.76, a quick ratio of 1.17 and a current ratio of 1.53. The firm has a 50 day moving average of $243.40 and a 200-day moving average of $243.35. Amgen Inc. has a 12 month low of $198.64 and a 12 month high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.25. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a return on equity of 218.34% and a net margin of 24.92%. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.38 EPS. Research analysts expect that Amgen Inc. will post 17.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th were paid a dividend of $1.94 per share. The ex-dividend date was Wednesday, August 17th. This represents a $7.76 annualized dividend and a dividend yield of 3.43%. Amgen’s payout ratio is 65.76%.

Amgen Company Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.